Aromatase expression and regulation in breast and endometrial cancer

Journal of Molecular Endocrinology

Volumn 57, Issue 1, 2016, Pages R19-R33

  Zhao, Hong ^a   Zhou, Ling ^a   Shangguan, Anna Junjie ^a   Bulun, Serdar E ^a  

^a NORTHWESTERN UNIVERSITY   (United States)

Author keywords

Aromatase; Breast cancer; Endometrial cancer; Estrogen

Indexed keywords

AROMATASE; ESTROGEN; PROTEIN BINDING; TRANSCRIPTION FACTOR;

ADIPOSE TISSUE; BIOSYNTHESIS; BREAST CANCER; BREAST CELL; BREAST DEVELOPMENT; CANCER RISK; CANCER TISSUE; CELL PROLIFERATION; DNA DAMAGE; ENDOMETRIUM CANCER; ENDOMETRIUM CELL; ENZYME REGULATION; ESTROGEN SYNTHESIS; FEMALE; GENETICALLY ENGINEERED MOUSE STRAIN; HUMAN; LONG TERM EXPOSURE; MENOPAUSE; METABOLITE; MOUSE MODEL; MURINE MODEL; NONHUMAN; OVARY; PREMENOPAUSE; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN EXPRESSION; REGULATORY SEQUENCE; REVIEW; SIGNAL TRANSDUCTION; SKIN; TRANSGENIC MOUSE; ANIMAL; ANTIBODY SPECIFICITY; BREAST TUMOR; DISEASE MODEL; ENDOMETRIUM TUMOR; GENE EXPRESSION REGULATION; GENETICS; METABOLISM; PATHOLOGY;

ANIMALS; AROMATASE; BREAST NEOPLASMS; DISEASE MODELS, ANIMAL; ENDOMETRIAL NEOPLASMS; ESTROGENS; FEMALE; GENE EXPRESSION REGULATION, ENZYMOLOGIC; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; ORGAN SPECIFICITY; PROMOTER REGIONS, GENETIC; PROTEIN BINDING; SIGNAL TRANSDUCTION; TRANSCRIPTION FACTORS;

EID: 84976609802     PISSN: 09525041     EISSN: 14796813     Source Type: Journal    
DOI: 10.1530/JME-15-0310     Document Type: Review

References (115)

1. Agarwal VR, Bulun SE, Leitch M, Rohrich R & Simpson ER 1996 Use of alternative promoters to express the aromatase cytochrome P450 (CYP19) gene in breast adipose tissues of cancer-free and breast cancer patients. Journal of Clinical Endocrinology and Metabolism 81 3843-3849.
2. Anderson GL & Neuhouser ML 2012 Obesity and the risk for premenopausal and postmenopausal breast cancer. Cancer Prevention Research 5 515-521. (doi:10.1158/1940-6207.CAPR-12-0091)
3. Anderson WF, Rosenberg PS & Katki HA 2014 Tracking and evaluating molecular tumor markers with cancer registry data: HER2 and breast cancer. Journal of National Cancer Institute 106 dju093. (doi:10.1093/jnci/dju093)
4. Arevalo MA, Azcoitia I & Garcia-Segura LM 2015 The neuroprotective actions of oestradiol and oestrogen receptors. Nature Review Neuroscience 16 17-29. (doi:10.1038/nrn3856)
5. Beresford SA, Weiss NS, Voigt LF & McKnight B 1997 Risk of endometrial cancer in relation to use of oestrogen combined with cyclic progestagen therapy in postmenopausal women. Lancet 349 458-461. (doi:10.1016/S0140-6736(96)07365-5)
6. Berstein L, Maximov S, Gershfeld E, Meshkova I, Gamajunova V, Tsyrlina E, Larionov A, Kovalevskij A & Vasilyev D 2002 Neoadjuvant therapy of endometrial cancer with the aromatase inhibitor letrozole: endocrine and clinical effects. European Journal of Obstetrics & Gynecology and Reproductive Biology 105 161-165.
7. Bokhman JV 1983 Two pathogenetic types of endometrial carcinoma. Gynecologic Oncology 15 10-17. (doi:10.1016/0090-8258(83)90111-7)
8. Boon WC, Chow JD & Simpson ER 2010 The multiple roles of estrogens and the enzyme aromatase. Progress Brain Research 181 209-232. (doi:10.1016/S0079-6123(08)81012-6)
9. Brodie A, Lu Q, Liu Y & Long B 1999a Aromatase inhibitors and their antitumor effects in model systems. Endocrine-Related Cancer 6 205-210.
10. Brodie A, Lu Q & Long B 1999b Aromatase and its inhibitors. Journal of Steroid Biochemistry and Molecular Biology 69 205-210.
11. Brown KA & Simpson ER 2010 Obesity and breast cancer: progress to understanding the relationship. Cancer Research 70 4-7. (doi:10.1158/0008-5472.CAN-09-2257)
12. Brown KA, McInnes KJ, Hunger NI, Oakhill JS, Steinberg GR & Simpson ER 2009 Subcellular localization of cyclic AMP-responsive element binding protein-regulated transcription coactivator 2 provides a link between obesity and breast cancer in postmenopausal women. Cancer Research 69 5392-5399. (doi:10.1158/0008-5472.CAN-09-0108)
13. Brown KA, Hunger NI, Docanto M & Simpson ER 2010 Metformin inhibits aromatase expression in human breast adipose stromal cells via stimulation of AMP-activated protein kinase. Breast Cancer Research Treatment 123 591-596. (doi:10.1007/s10549-010-0834-y)
14. Brueggemeier RW, Richards JA & Petrel TA 2003 Aromatase and cyclooxygenases: enzymes in breast cancer. Journal of Steroid Biochemistry and Molecular Biology 86 501-507. (doi:10.1016/S0960-0760(03)00380-7)
15. Bulun SE 2009 Endometriosis. New England Journal of Medicine 360 268-279. (doi:10.1056/NEJMra0804690)
16. Bulun SE, Price TM, Aitken J, Mahendroo MS & Simpson ER 1993 A link between breast cancer and local estrogen biosynthesis suggested by quantification of breast adipose tissue aromatase cytochrome P450 transcripts using competitive polymerase chain reaction after reverse transcription. Journal of Clinical Endocrinology and Metabolism 77 1622-1628.
17. Bulun SE, Economos K, Miller D & Simpson ER 1994 CYP19 (aromatase cytochrome P450) gene expression in human malignant endometrial tumors. Journal of Clinical Endocrinology and Metabolism 79 1831-1834.
18. Bulun SE, Yang S, Fang Z, Gurates B, Tamura M, Zhou J & Sebastian S 2001 Role of aromatase in endometrial disease. Journal of Steroid Biochemistry and Molecular Biology 79 19-25. (doi:10.1016/S0960-0760(01)00134-0)
19. Bulun SE, Lin Z, Imir G, Amin S, Demura M, Yilmaz B, Martin R, Utsunomiya H, Thung S, Gurates B, et al. 2005 Regulation of aromatase expression in estrogen-responsive breast and uterine disease: from bench to treatment. Pharmacological Reviews 57 359-383. (doi:10.1124/pr.57.3.6)
20. Bulun SE, Lin Z, Zhao H, Lu M, Amin S, Reierstad S & Chen D 2009 Regulation of aromatase expression in breast cancer tissue. Annals of the New York Academy of Sciences 1155 121-131. (doi:10.1111/j.1749-6632.2009.03705.x)
21. Bulun SE, Chen D, Moy I, Brooks DC & Zhao H 2012 Aromatase, breast cancer and obesity: a complex interaction. Trends in Endocrinology and Metabolism 23 83-89. (doi:10.1016/j.tem.2011.10.003)
22. Calle EE, Rodriguez C, Walker-Thurmond K & Thun MJ 2003 Overweight, obesity, and mortality from cancer in a prospectively studied cohort of U.S. adults. New England Journal of Medicine 348 1625-1638.
23. Cancer Genome Atlas Network 2012 Comprehensive molecular portraits of human breast tumours. Nature 490 61-70. (doi:10.1038/nature11412)
24. Cavalieri E, Chakravarti D, Guttenplan J, Hart E, Ingle J, Jankowiak R, Muti P, Rogan E, Russo J, Santen R, et al. 2006 Catechol estrogen quinones as initiators of breast and other human cancers: implications for biomarkers of susceptibility and cancer prevention. Biochimica et Biophysica Acta 1766 63-78.
25. Chen S, Zhou D, Yang C, Okubo T, Kinoshita Y, Yu B, Kao YC & Itoh T 2001 Modulation of aromatase expression in human breast tissue. Journal of Steroid Biochemistry and Molecular Biology 79 35-40. (doi:10.1016/S0960-0760(01)00132-7)
26. Chen D, Reierstad S, Lin Z, Lu M, Brooks C, Li N, Innes J & Bulun SE 2007 Prostaglandin E(2) induces breast cancer related aromatase promoters via activation of p38 and c-Jun NH(2)-terminal kinase in adipose fibroblasts. Cancer Research 67 8914-8922. (doi:10.1158/0008-5472.CAN-06-4751)
27. Chen D, Reierstad S, Lu M, Lin Z, Ishikawa H & Bulun SE 2009 Regulation of breast cancer-associated aromatase promoters. Cancer Letters 273 15-27. (doi:10.1016/j.canlet.2008.05.038)
28. Chen D, Reierstad S, Fang F & Bulun SE 2011 JunD and JunB integrate prostaglandin E2 activation of breast cancer-associated proximal aromatase promoters. Molecular Endocrinology 25 767-775. (doi:10.1210/me.2010-0368)
29. Chen D, Zhao H, Coon JS IV, Ono M, Pearson EK & Bulun SE 2012 Weight gain increases human aromatase expression in mammary gland. Molecular and Cellular Endocrinology 355 114-120. (doi:10.1016/j.mce.2012.01.027)
30. Chen JY, Kuo SJ, Liaw YP, Avital I, Stojadinovic A, Man YG, Mannion C, Wang J, Chou MC, Tsai HD, et al. 2014 Endometrial cancer incidence in breast cancer patients correlating with age and duration of tamoxifen use: a population based study. Journal of Cancer 5 151-155. (doi:10.7150/jca.8412)
31. Chow JD, Simpson ER & Boon WC 2009 Alternative 5'-untranslated first exons of the mouse Cyp19A1 (aromatase) gene. Journal of Steroid Biochemistry and Molecular Biology 115 115-125. (doi:10.1016/j. jsbmb.2009.03.010)
32. Clyne CD, Speed CJ, Zhou J & Simpson ER 2002 Liver receptor homologue-1 (LRH-1) regulates expression of aromatase in preadipocytes. Journal of Biological Chemistry 277 20591-20597. (doi:10.1074/jbc.M201117200)
33. Cos S, Alvarez-Garcia V, Gonzalez A, Alonso-Gonzalez C & Martinez-Campa C 2014 Melatonin modulation of crosstalk among malignant epithelial, endothelial and adipose cells in breast cancer (review). Oncology Letters 8 487-492.
34. Couse JF, Hewitt SC, Bunch DO, Sar M, Walker VR, Davis BJ & Korach KS 1999 Postnatal sex reversal of the ovaries in mice lacking estrogen receptors alpha and beta. Science 286 2328-2331. (doi:10.1126/science.286.5448.2328)
35. Creasman WT 1997 Endometrial cancer: incidence, prognostic factors, diagnosis, and treatment. Seminars in Oncology 24 S1-140-S141-150.
36. Cui J, Shen Y & Li R 2013 Estrogen synthesis and signaling pathways during aging: from periphery to brain. Trends in Molecular Medicine 19 197-209. (doi:10.1016/j.molmed.2012.12.007)
37. Diaz-Cruz ES, Shapiro CL & Brueggemeier RW 2005 Cyclooxygenase inhibitors suppress aromatase expression and activity in breast cancer cells. Journal of Clinical Endocrinology and Metabolism 90 2563-2570. (doi:10.1210/jc.2004-2029)
38. Diaz-Cruz ES, Sugimoto Y, Gallicano GI, Brueggemeier RW & Furth PA 2011 Comparison of increased aromatase versus ERalpha in the generation of mammary hyperplasia and cancer. Cancer Research 71 5477-5487. (doi:10.1158/0008-5472.CAN-10-4652)
39. Dunbier AK, Anderson H, Ghazoui Z, Folkerd EJ, A'Hern R, Crowder RJ, Hoog J, Smith IE, Osin P, Nerurkar A, et al. 2010 Relationship between plasma estradiol levels and estrogen-responsive gene expression in estrogen receptor-positive breast cancer in postmenopausal women. Journal of Clinical Oncology 28 1161-1167. (doi:10.1200/JCO.2009.23.9616)
40. Dupont S, Krust A, Gansmuller A, Dierich A, Chambon P & Mark M 2000 Effect of single and compound knockouts of estrogen receptors alpha (ERalpha) and beta (ERbeta) on mouse reproductive phenotypes. Development 127 4277-4291.
41. Fujisawa C & Castellot JJ Jr 2014 Matrix production and remodeling as therapeutic targets for uterine leiomyoma. Journal of Cell Communication and Signaling 8 179-194. (doi:10.1007/s12079-014-0234-x)
42. Gibson DA, McInnes KJ, Critchley HO & Saunders PT 2013 Endometrial intracrinology-generation of an estrogen-dominated microenvironment in the secretory phase of women. Journal of Clinical Endocrinology and Metabolism 98 E1802-E1806. (doi:10.1210/ jc.2013-2140)
43. Golovine K, Schwerin M & Vanselow J 2003 Three different promoters control expression of the aromatase cytochrome p450 gene (cyp19) in mouse gonads and brain. Biology of Reproduction 68 978-984. (doi:10.1095/biolreprod.102.008037)
44. Grodin JM, Siiteri PK & MacDonald PC 1973 Source of estrogen production in postmenopausal women. Journal of Clinical Endocrinology and Metabolsim 36 207-214. (doi:10.1210/ jcem-36-2-207)
45. Guillemette C, Belanger A & Lepine J 2004 Metabolic inactivation of estrogens in breast tissue by UDP-glucuronosyltransferase enzymes: an overview. Breast Cancer Research 6 246-254. (doi:10.1186/bcr936)
46. Gunter MJ, Hoover DR, Yu H, Wassertheil-Smoller S, Rohan TE, Manson JE, Li J, Ho GY, Xue X, Anderson GL, et al. 2009 Insulin, insulin-like growth factor-I, and risk of breast cancer in postmenopausal women. Journal of National Cancer Institute 101 48-60. (doi:10.1093/jnci/djn415)
47. Hankinson SE, Willett WC, Manson JE, Colditz GA, Hunter DJ, Spiegelman D, Barbieri RL & Speizer FE 1998 Plasma sex steroid hormone levels and risk of breast cancer in postmenopausal women. Journal of National Cancer Institute 90 1292-1299. (doi:10.1093/ jnci/90.17.1292)
48. Harada N 1997 Aberrant expression of aromatase in breast cancer tissues. Journal of Steroid Biochemistry and Molecular Biology 61 175-184. (doi:10.1016/S0960-0760(97)80010-6)
49. Harris HR, Willett WC, Terry KL & Michels KB 2011 Body fat distribution and risk of premenopausal breast cancer in the Nurses' Health Study II. Journal of National Cancer Institute 103 273-278. (doi:10.1093/jnci/djq500)
50. Haynes BP, Straume AH, Geisler J, A'Hern R, Helle H, Smith IE, Lonning PE & Dowsett M 2010 Intratumoral estrogen disposition in breast cancer. Clinical Cancer Research 16 1790-1801. (doi:10.1158/1078-0432.CCR-09-2481)
51. Hemsell DL, Grodin JM, Brenner PF, Siiteri PK & MacDonald PC 1974 Plasma precursors of estrogen. II. Correlation of the extent of conversion of plasma androstenedione to estrone with age. Journal of Clinical Endocrinology and Metabolism 38 476-479. (doi:10.1210/jcem-38-3-476)
52. Honda S, Harada N & Takagi Y 1994 Novel exon 1 of the aromatase gene specific for aromatase transcripts in human brain. Biochemical and Biophysics Research Communications 198 1153-1160. (doi:10.1006/bbrc.1994.1163)
53. Honda S, Harada N & Takagi Y 1996 The alternative exons 1 of the mouse aromatase cytochrome P-450 gene. Biochimica et Biophysica Acta 1305 145-150. (doi:10.1016/0167-4781(95)00200-6)
54. Huang Z, Hankinson SE, Colditz GA, Stampfer MJ, Hunter DJ, Manson JE, Hennekens CH, Rosner B, Speizer FE & Willett WC 1997 Dual effects of weight and weight gain on breast cancer risk. JAMA 278 1407-1411. (doi:10.1001/jama.1997.03550170037029)
55. Jarzabek K, Koda M, Walentowicz-Sadlecka M, Grabiec M, Laudanski P & Wolczynski S 2013 Altered expression of ERs, aromatase, and COX2 connected to estrogen action in type 1 endometrial cancer biology. Tumour Biology 34 4007-4016. (doi:10.1007/s13277-013-0991-9)
56. John EM, Sangaramoorthy M, Phipps AI, Koo J & Horn-Ross PL 2011 Adult body size, hormone receptor status, and premenopausal breast cancer risk in a multiethnic population: the San Francisco Bay Area breast cancer study. American Journal of Epidemiology 173 201-216. (doi:10.1093/aje/kwq345)
57. Jones ME, Thorburn AW, Britt KL, Hewitt KN, Misso ML, Wreford NG, Proietto J, Oz OK, Leury BJ, Robertson KM, et al. 2001 Aromatasedeficient (ArKO) mice accumulate excess adipose tissue. Journal of Steroid Biochemistry and Molecular Biology 79 3-9. (doi:10.1016/S0960-0760(01)00136-4)
58. Key TJ & Pike MC 1988 The dose-effect relationship between 'unopposed' oestrogens and endometrial mitotic rate: its central role in explaining and predicting endometrial cancer risk. British Journal of Cancer 57 205-212. (doi:10.1038/bjc.1988.44)
59. Kim JJ, Kurita T & Bulun SE 2013 Progesterone action in endometrial cancer, endometriosis, uterine fibroids, and breast cancer. Endocrine Reviews 34 130-162. (doi:10.1210/er.2012-1043)
60. Kirma N, Gill K, Mandava U & Tekmal RR 2001 Overexpression of aromatase leads to hyperplasia and changes in the expression of genes involved in apoptosis, cell cycle, growth, and tumor suppressor functions in the mammary glands of transgenic mice. Cancer Research 61 1910-1918.
61. Kohler BA, Sherman RL, Howlader N, Jemal A, Ryerson AB, Henry KA, Boscoe FP, Cronin KA, Lake A, Noone AM, et al. 2015 Annual report to the nation on the status of cancer, 1975-2011, featuring incidence of breast cancer subtypes by race/ethnicity, poverty, and state. Journal of National Cancer Institute 107 djv048. (doi:10.1093/jnci/djv048)
62. Kotov A, Falany JL, Wang J & Falany CN 1999 Regulation of estrogen activity by sulfation in human Ishikawa endometrial adenocarcinoma cells. Journal of Steroid Biochemistry and Molecular Biology 68 137-144. (doi:10.1016/S0960-0760(99)00022-9)
63. Krege JH, Hodgin JB, Couse JF, Enmark E, Warner M, Mahler JF, Sar M, Korach KS, Gustafsson JA & Smithies O 1998 Generation and reproductive phenotypes of mice lacking estrogen receptor beta. PNAS 95 15677-15682. (doi:10.1073/pnas.95.26.15677)
64. Li X & Rahman N 2008 Impact of androgen/estrogen ratio: lessons learned from the aromatase over-expression mice. General and Comparative Endocrinology 159 1-9. (doi:10.1016/j.ygcen.2008.07.025)
65. Li X, Nokkala E, Yan W, Streng T, Saarinen N, Warri A, Huhtaniemi I, Santti R, Makela S & Poutanen M 2001 Altered structure and function of reproductive organs in transgenic male mice overexpressing human aromatase. Endocrinology 142 2435-2442.
66. Li X, Warri A, Makela S, Ahonen T, Streng T, Santti R & Poutanen M 2002 Mammary gland development in transgenic male mice expressing human P450 aromatase. Endocrinology 143 4074-4083. (doi:10.1210/en.2002-220181)
67. Liu YX & Hsueh AJ 1986 Synergism between granulosa and thecainterstitial cells in estrogen biosynthesis by gonadotropin-treated rat ovaries: studies on the two-cell, two-gonadotropin hypothesis using steroid antisera. Biology of Reproduction 35 27-36. (doi:10.1095/ biolreprod35.1.27)
68. Lonning PE, Haynes BP, Straume AH, Dunbier A, Helle H, Knappskog S & Dowsett M 2011 Exploring breast cancer estrogen disposition: the basis for endocrine manipulation. Clinical Cancer Research 17 4948-4958. (doi:10.1158/1078-0432.CCR-11-0043)
69. Lubahn DB, Moyer JS, Golding TS, Couse JF, Korach KS & Smithies O 1993 Alteration of reproductive function but not prenatal sexual development after insertional disruption of the mouse estrogen receptor gene. PNAS 90 11162-11166. (doi:10.1073/ pnas.90.23.11162)
70. MacDonald PC, Grodin JM & Siiteri PK 1968 The utilization of plasma androstenedione for estrone production in women. In Progress in Endocrinology, Proceedings of the Third International Congress of Endocrinology, 30 June-5 July 1968, Mexico, Excerpta Medica International Congress Series No. 184, pp 770-776. Eds C Gual & FJG Ebling. Amsterdam, The Netherlands: Excerpta Medica Foundation.
71. Meng L, Zhou J, Sasano H, Suzuki T, Zeitoun KM & Bulun SE 2001 Tumor necrosis factor alpha and interleukin 11 secreted by malignant breast epithelial cells inhibit adipocyte differentiation by selectively downregulating CCAAT/enhancer binding protein alpha and peroxisome proliferator-activated receptor gamma: mechanism of desmoplastic reaction. Cancer Research 61 2250-2255.
72. Morice P, Leary A, Creutzberg C, Abu-Rustum N & Darai E 2016 Endometrial cancer. Lancet 387 1094-1108. (doi:10.1016/S0140-6736(15)00130-0)
73. Morimoto LM, White E, Chen Z, Chlebowski RT, Hays J, Kuller L, Lopez AM, Manson J, Margolis KL, Muti PC, et al. 2002 Obesity, body size, and risk of postmenopausal breast cancer: the Women's Health Initiative (United States). Cancer Causes Control 13 741-751. (doi:10.1023/A:1020239211145)
74. Nagasako S, Asanuma N & Nagata Y 1988 [Plasma concentration of estrogens and androgens in postmenopausal women with or without endometrial cancer]. Nihon Sanka Fujinka Gakkai Zasshi 40 707-713.
75. Nakamura T, Imai Y, Matsumoto T, Sato S, Takeuchi K, Igarashi K, Harada Y, Azuma Y, Krust A, Yamamoto Y, et al. 2007 Estrogen prevents bone loss via estrogen receptor alpha and induction of Fas ligand in osteoclasts. Cell 130 811-823. (doi:10.1016/j.cell.2007.07.025)
76. Noble LS, Simpson ER, Johns A & Bulun SE 1996 Aromatase expression in endometriosis. Journal of Clinical Endocrinology and Metabolism 81 174-179.
77. O'Lone R, Knorr K, Jaffe IZ, Schaffer ME, Martini PG, Karas RH, Bienkowska J, Mendelsohn ME & Hansen U 2007 Estrogen receptors alpha and beta mediate distinct pathways of vascular gene expression, including genes involved in mitochondrial electron transport and generation of reactive oxygen species. Molecular Endocrinology 21 1281-1296. (doi:10.1210/me.2006-0497)
78. Perou CM, Sorlie T, Eisen MB, van de Rijn M, Jeffrey SS, Rees CA, Pollack JR, Ross DT, Johnsen H, Akslen LA, et al. 2000 Molecular portraits of human breast tumours. Nature 406 747-752. (doi:10.1038/35021093)
79. Potischman N, Hoover RN, Brinton LA, Siiteri P, Dorgan JF, Swanson CA, Berman ML, Mortel R, Twiggs LB, Barrett RJ, et al. 1996 Case-control study of endogenous steroid hormones and endometrial cancer. Journal of National Cancer Institute 88 1127-1135. (doi:10.1093/ jnci/88.16.1127)
80. Price T, Aitken J, Head J, Mahendroo M, Means G & Simpson E 1992 Determination of aromatase cytochrome P450 messenger ribonucleic acid in human breast tissue by competitive polymerase chain reaction amplification. Journal of Clinical Endocrinology and Metabolism 74 1247-1252.
81. Rizner TL 2013 Estrogen biosynthesis, phase I and phase II metabolism, and action in endometrial cancer. Molecular and Cellular Endocrinology 381 124-139. (doi:10.1016/j.mce.2013.07.026)
82. Rossouw JE, Anderson GL, Prentice RL, LaCroix AZ, Kooperberg C, Stefanick ML, Jackson RD, Beresford SA, Howard BV, Johnson KC, et al. 2002 Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women's Health Initiative randomized controlled trial. JAMA 288 321-333.
83. Roy D & Liehr JG 1999 Estrogen, DNA damage and mutations. Mutations Research 424 107-115. (doi:10.1016/S0027-5107(99)00012-3)
84. Santen RJ 1981 Suppression of estrogens with aminoglutethimide and hydrocortisone (medical adrenalectomy) as treatment of advanced breast carcinoma: a review. Breast Cancer Research Treatment 1 183-202. (doi:10.1007/BF01806259)
85. Santen RJ, Yue W & Wang JP 2015 Estrogen metabolites and breast cancer. Steroids 99 61-66. (doi:10.1016/j.steroids.2014.08.003)
86. Sebastian S & Bulun SE 2001 A highly complex organization of the regulatory region of the human CYP19 (aromatase) gene revealed by the Human Genome Project. Journal of Clinical Endocrinology and Metabolism 86 4600-4602. (doi:10.1210/jcem.86.10.7947)
87. Sebastian S, Takayama K, Shozu M & Bulun SE 2002 Cloning and characterization of a novel endothelial promoter of the human CYP19 (aromatase P450) gene that is up-regulated in breast cancer tissue. Molecular Endocrinology 16 2243-2254. (doi:10.1210/me.2002-0123)
88. Sherman ME, Sturgeon S, Brinton LA, Potischman N, Kurman RJ, Berman ML, Mortel R, Twiggs LB, Barrett RJ & Wilbanks GD 1997 Risk factors and hormone levels in patients with serous and endometrioid uterine carcinomas. Modern Pathology 10 963-968.
89. Shibutani S, Ravindernath A, Suzuki N, Terashima I, Sugarman SM, Grollman AP & Pearl ML 2000 Identification of tamoxifen-DNA adducts in the endometrium of women treated with tamoxifen. Carcinogenesis 21 1461-1467. (doi:10.1093/carcin/21.8.1461)
90. Shozu M, Sebastian S, Takayama K, Hsu WT, Schultz RA, Neely K, Bryant M & Bulun SE 2003 Estrogen excess associated with novel gain-of-function mutations affecting the aromatase gene. New England Journal of Medicine 348 1855-1865. (doi:10.1056/NEJMoa021559)
91. Siiteri PK 1978 Steroid hormones and endometrial cancer. Cancer Research 38 4360-4366.
92. Simpson ER 2003 Sources of estrogen and their importance. Journal of Steroid Biochemistry and Molecular Biology 86 225-230. (doi:10.1016/ S0960-0760(03)00360-1)
93. Simpson E & Santen RJ 2015 Celebrating 75 years of oestradiol. Journal of Molecular Endocrinology 55 T1-T20. (doi:10.1530/JME-15-0128)
94. Simpson ER, Mahendroo MS, Means GD, Kilgore MW, Hinshelwood MM, Graham-Lorence S, Amarneh B, Ito Y, Fisher CR, Michael MD, et al. 1994 Aromatase cytochrome P450, the enzyme responsible for estrogen biosynthesis. Endocrine Reviews 15 342-355.
95. Sofi M, Young MJ, Papamakarios T, Simpson ER & Clyne CD 2003 Role of CRE-binding protein (CREB) in aromatase expression in breast adipose. Breast Cancer Research Treatment 79 399-407. (doi:10.102 3/A:1024038632570)
96. Suzuki T, Miki Y, Nakamura Y, Moriya T, Ito K, Ohuchi N & Sasano H 2005 Sex steroid-producing enzymes in human breast cancer. Endocrine Related Cancer 12 701-720. (doi:10.1677/erc.1.00834)
97. Swerdlow AJ, Jones ME & British Tamoxifen Second Cancer Study G 2005 Tamoxifen treatment for breast cancer and risk of endometrial cancer: a case-control study. Journal of National Cancer Institute 97 375-384.
98. Tekmal RR, Ramachandra N, Gubba S, Durgam VR, Mantione J, Toda K, Shizuta Y & Dillehay DL 1996 Overexpression of int-5/aromatase in mammary glands of transgenic mice results in the induction of hyperplasia and nuclear abnormalities. Cancer Research 56 3180-3185.
99. Tong MH, Jiang H, Liu P, Lawson JA, Brass LF & Song WC 2005 Spontaneous fetal loss caused by placental thrombosis in estrogen sulfotransferase-deficient mice. Nature Medicine 11 153-159. (doi:10.1038/nm1184)
100. Utsumi T, Harada N, Maruta M & Takagi Y 1996 Presence of alternatively spliced transcripts of aromatase gene in human breast cancer. Journal of Clinical Endocrinology and Metabolism 81 2344-2349.
101. Watanabe K, Sasano H, Harada N, Ozaki M, Niikura H, Sato S & Yajima A 1995 Aromatase in human endometrial carcinoma and hyperplasia. Immunohistochemical, in situ hybridization, and biochemical studies. American Journal of Pathology 146 491-500.
102. White KK, Park SY, Kolonel LN, Henderson BE & Wilkens LR 2012 Body size and breast cancer risk: the multiethnic cohort. International Journal of Cancer 131 E705-E716. (doi:10.1002/ijc.27373)
103. Yada H, Hosokawa K, Tajima K, Hasegawa Y & Kotsuji F 1999 Role of ovarian theca and granulosa cell interaction in hormone productionand cell growth during the bovine follicular maturation process. Biology of Reproduction 61 1480-1486. (doi:10.1095/biolreprod61.6.1480)
104. Yamamoto T, Kitawaki J, Urabe M, Honjo H, Tamura T, Noguchi T, Okada H, Sasaki H, Tada A, Terashima Y, et al. 1993 Estrogen productivity of endometrium and endometrial cancer tissue: influence of aromatase on proliferation of endometrial cancer cells. Journal of Steroid Biochemistry and Molecular Biology 44 463-468. (doi:10.1016/0960-0760(93)90251-Q)
105. Zhao Y, Mendelson CR & Simpson ER 1995a Characterization of the sequences of the human CYP19 (aromatase) gene that mediate regulation by glucocorticoids in adipose stromal cells and fetal hepatocytes. Molecular Endocrinology 9 340-349.
106. Zhao Y, Nichols JE, Bulun SE, Mendelson CR & Simpson ER 1995b Aromatase P450 gene expression in human adipose tissue. Role of a Jak/STAT pathway in regulation of the adipose-specific promoter. Journal of Biological Chemistry 270 16449-16457.
107. Zhao Y, Agarwal VR, Mendelson CR & Simpson ER 1996a Estrogen biosynthesis proximal to a breast tumor is stimulated by PGE2 via cyclic AMP, leading to activation of promoter II of the CYP19 (aromatase) gene. Endocrinology 137 5739-5742.
108. Zhao Y, Nichols JE, Valdez R, Mendelson CR & Simpson ER 1996b Tumor necrosis factor-alpha stimulates aromatase gene expression in human adipose stromal cells through use of an activating protein-1 binding site upstream of promoter 1.4. Molecular Endocrinology 10 1350-1357.
109. Zhao H, Innes J, Brooks DC, Reierstad S, Yilmaz MB, Lin Z & Bulun SE 2009 A novel promoter controls Cyp19a1 gene expression in mouse adipose tissue. Reproductive Biology and Endocrinology 7 37. (doi:10.1186/1477-7827-7-37)
110. Zhao H, Pearson EK, Brooks DC, Coon JS IV, Chen D, Demura M, Zhang M, Clevenger CV, Xu X, Veenstra TD, et al. 2012 A humanized pattern of aromatase expression is associated with mammary hyperplasia in mice. Endocrinology 153 2701-2713. (doi:10.1210/en.2011-1761)
111. Zhou D & Chen S 1999 Identification and characterization of a cAMPresponsive element in the region upstream from promoter 1.3 of the human aromatase gene. Archives of Biochemistry and Biophysics 371 179190. (doi:10.1006/abbi.1999.1454)
112. Zhou C, Zhou D, Esteban J, Murai J, Siiteri PK, Wilczynski S & Chen S 1996 Aromatase gene expression and its exon I usage in human breast tumors. Detection of aromatase messenger RNA by reverse transcription-polymerase chain reaction. Journal of Steroid Biochemistry and Molecular Biology 59 163-171. (doi:10.1016/S0960-0760(96)00100-8)
113. Zhou D, Zhou C & Chen S 1997 Gene regulation studies of aromatase expression in breast cancer and adipose stromal cells. Journal of Steroid Biochemistry and Molecular Biology 61 273-280. (doi:10.1016/ S0960-0760(97)80023-4)
114. Zhou J, Gurates B, Yang S, Sebastian S & Bulun SE 2001 Malignant breast epithelial cells stimulate aromatase expression via promoter II in human adipose fibroblasts: an epithelial-stromal interaction in breast tumors mediated by CCAAT/enhancer binding protein beta. Cancer Research 61 2328-2334.
115. Ziegler RG, Hoover RN, Nomura AM, West DW, Wu AH, Pike MC, Lake AJ, Horn-Ross PL, Kolonel LN, Siiteri PK, et al. 1996 Relative weight, weight change, height, and breast cancer risk in Asian-American women. Journal of National Cancer Institute 88 650-660. (doi:10.1093/jnci/88.10.650)